Total Payments
$213,275
2024 Payments
$10,470
Companies
36
Transactions
719
Medicare Patients
5,166
Medicare Billing
$491,278
Payment Breakdown by Category
Other$182,030 (85.3%)
Travel$16,745 (7.9%)
Food & Beverage$10,983 (5.1%)
Consulting$3,342 (1.6%)
Education$175.83 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $182,030 | 108 | 85.3% |
| Travel and Lodging | $16,745 | 102 | 7.9% |
| Food and Beverage | $10,983 | 495 | 5.1% |
| Consulting Fee | $3,342 | 6 | 1.6% |
| Education | $175.83 | 8 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sunovion Pharmaceuticals Inc. | $131,355 | 228 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $48,918 | 105 | $0 (2024) |
| Mylan Specialty L.P. | $28,254 | 90 | $0 (2024) |
| GlaxoSmithKline, LLC. | $2,163 | 142 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $745.29 | 34 | $0 (2024) |
| Electromed, Inc. | $292.43 | 28 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $153.38 | 3 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $133.05 | 9 | $0 (2024) |
| GENZYME CORPORATION | $125.19 | 8 | $0 (2024) |
| Philips Electronics North America Corporation | $107.24 | 7 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,470 | 97 | AstraZeneca Pharmaceuticals LP ($8,992) |
| 2023 | $10,030 | 75 | AstraZeneca Pharmaceuticals LP ($7,279) |
| 2022 | $12,564 | 59 | AstraZeneca Pharmaceuticals LP ($10,067) |
| 2021 | $11,372 | 65 | AstraZeneca Pharmaceuticals LP ($9,418) |
| 2020 | $21,873 | 54 | AstraZeneca Pharmaceuticals LP ($13,073) |
| 2019 | $63,384 | 164 | Sunovion Pharmaceuticals Inc. ($48,901) |
| 2018 | $72,891 | 166 | Sunovion Pharmaceuticals Inc. ($72,205) |
| 2017 | $10,691 | 39 | Sunovion Pharmaceuticals Inc. ($10,232) |
All Payment Transactions
719 individual payment records from CMS Open Payments — Page 1 of 29
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Philips North America LLC | (8874) inCourage (Device) | Food and Beverage | Cash or cash equivalent | $17.51 | General |
| Category: Medical Device | ||||||
| 12/11/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $7.13 | General |
| Category: RESPIRATORY | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: Respiratory | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $17.61 | General |
| Category: Respiratory | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $19.24 | General |
| Category: Respiratory | ||||||
| 11/26/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $29.48 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,350.00 | General |
| Category: Respiratory | ||||||
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $950.00 | General |
| Category: Respiratory | ||||||
| 11/21/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $14.12 | General |
| Category: RESPIRATORY | ||||||
| 11/21/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $0.85 | General |
| Category: RESPIRATORY | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $18.58 | General |
| Category: Respiratory | ||||||
| 11/18/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $13.42 | General |
| Category: Inflammation | ||||||
| 11/13/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $18.33 | General |
| Category: Respiratory | ||||||
| 11/12/2024 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $17.10 | General |
| Category: Pulmonology | ||||||
| 11/06/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $19.24 | General |
| Category: IMMUNOLOGY | ||||||
| 11/05/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $13.62 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/30/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $14.26 | General |
| Category: Immunology | ||||||
| 10/29/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $13.40 | General |
| Category: RESPIRATORY | ||||||
| 10/28/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $14.37 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 10/24/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $16.41 | General |
| Category: RESPIRATORY | ||||||
| 10/22/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $19.48 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 10/22/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $16.68 | General |
| Category: Respiratory | ||||||
| 10/15/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $12.67 | General |
| Category: HFCWO | ||||||
| 10/14/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $17.37 | General |
| Category: IMMUNOLOGY | ||||||
| 10/08/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $16.22 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 1,087 | 1,492 | $284,200 | $102,936 |
| 2022 | 15 | 1,290 | 1,817 | $348,044 | $120,067 |
| 2021 | 14 | 1,264 | 1,879 | $369,736 | $136,394 |
| 2020 | 18 | 1,525 | 2,223 | $400,383 | $131,881 |
Total Patients
5,166
Total Services
7,411
Medicare Billing
$491,278
Procedure Codes
71
All Medicare Procedures & Services
71 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 335 | 645 | $143,835 | $56,957 | 39.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 56 | 113 | $25,086 | $10,345 | 41.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 140 | 158 | $24,016 | $9,920 | 41.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 85 | 85 | $28,730 | $8,893 | 31.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 56 | 61 | $25,559 | $8,124 | 31.8% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Office | 2023 | 22 | 24 | $10,320 | $2,184 | 21.2% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2023 | 18 | 19 | $7,619 | $1,713 | 22.5% |
| 94618 | Test for exercise-induced lung stress | Facility | 2023 | 60 | 62 | $4,278 | $1,039 | 24.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 12 | 16 | $2,480 | $973.12 | 39.2% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2023 | 94 | 96 | $3,168 | $864.04 | 27.3% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 93 | 95 | $2,375 | $634.62 | 26.7% |
| 95806 | Sleep study including heart rate, breathing, airflow, and effort | Office | 2023 | 20 | 20 | $3,780 | $607.15 | 16.1% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2023 | 50 | 50 | $1,850 | $392.50 | 21.2% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2023 | 46 | 48 | $1,104 | $290.02 | 26.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 334 | 612 | $135,344 | $53,380 | 39.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 90 | 289 | $64,158 | $22,568 | 35.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 86 | 101 | $42,319 | $15,036 | 35.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 138 | 158 | $23,809 | $9,901 | 41.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 74 | 74 | $24,913 | $8,385 | 33.7% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Office | 2022 | 21 | 22 | $10,957 | $2,371 | 21.6% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2022 | 24 | 25 | $10,025 | $1,789 | 17.8% |
| 94618 | Test for exercise-induced lung stress | Facility | 2022 | 79 | 79 | $5,451 | $1,350 | 24.8% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2022 | 122 | 123 | $4,005 | $1,149 | 28.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 12 | 17 | $2,635 | $924.69 | 35.1% |
| 31624 | Irrigation and suction of lung airways to obtain cells using an endoscope | Facility | 2022 | 13 | 13 | $8,541 | $883.95 | 10.3% |
About Dr. Umer Siddiqui, M.D
Dr. Umer Siddiqui, M.D is a Pulmonary Disease healthcare provider based in Washington, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1245251321.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Umer Siddiqui, M.D has received a total of $213,275 in payments from pharmaceutical and medical device companies, with $10,470 received in 2024. These payments were reported across 719 transactions from 36 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($182,030).
As a Medicare-enrolled provider, Siddiqui has provided services to 5,166 Medicare beneficiaries, totaling 7,411 services with total Medicare billing of $491,278. Data is available for 4 years (2020–2023), covering 71 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Pulmonary Disease
- Location Washington, MO
- Active Since 07/22/2006
- Last Updated 12/16/2014
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1245251321
Products in Payments
- LONHALA MAGNAIR (Drug) $106,386
- BREZTRI (Drug) $35,038
- Yupelri (Drug) $25,939
- UTIBRON (Drug) $24,901
- BREZTRI AEROSPHERE (Drug) $12,997
- YUPELRI (Drug) $2,216
- TRELEGY ELLIPTA (Drug) $985.48
- NUCALA (Biological) $463.63
- FASENRA (Biological) $365.04
- AREXVY (Drug) $336.08
- SMARTVEST (Device) $292.43
- DUPIXENT (Biological) $241.71
- TEZSPIRE (Biological) $226.62
- ANORO (Drug) $210.50
- STIOLTO RESPIMAT (Drug) $149.86
- UPTRAVI (Drug) $141.24
- OFEV (Drug) $131.76
- GLASSIA (Biological) $115.82
- SYMBICORT (Drug) $101.04
- Arikayce (Drug) $93.19
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Washington
Andrew Shorr, Md, MD
Pulmonary Disease — Payments: $696,801
Pulmonary Disease $696,801
Leslie Kingslow, Md, MD
Pulmonary Disease — Payments: $32,019
Pulmonary Disease $32,019
Dr. Suliman Alamro, M.d, M.D
Pulmonary Disease — Payments: $9,387
Pulmonary Disease $9,387
Dr. Karen Fagan, Md, MD
Pulmonary Disease — Payments: $8,801
Pulmonary Disease $8,801
Dr. Jacob Collen, M.d, M.D
Pulmonary Disease — Payments: $7,783
Pulmonary Disease $7,783
Dr. Steven Lerner, M.d, M.D
Pulmonary Disease — Payments: $7,003
Pulmonary Disease $7,003